Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

• Conditions: Adult Acute Myeloid Leukemia

• Registration Number: NCT03283228
• Lead Sponsor: Assiut University

Brief Summary

1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Detailed Description

1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.

2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Study Timeline

• Study First Submitted: 2017-08-27
• Status Verified: 2017-09
• Study First Submitted QC: 2017-09-12
• Last Update Submitted: 2017-09-12
• Study First Posted: 2017-09-14
• Last Update Posted: 2017-09-14
• Study Start: 2017-12-01
• Primary Completion: 2018-12-01
• Study Completion: 2019-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Anew diagnosis cases of adult AML

Exclusion Criteria

1. Pediatric AML .
2. follow up cases of adult AML

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CD11b and CD56 marker	24 month	Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.